Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Zhaoke Ophthalmology's share price for the quarter that ended in Dec. 2023 was HK$3.95. Zhaoke Ophthalmology's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 546.14 Mil. Therefore, Zhaoke Ophthalmology's market cap for the quarter that ended in Dec. 2023 was HK$2,157.25 Mil.
Zhaoke Ophthalmology's quarterly market cap
increased
from Dec. 2022 (HK$1,642.41 Mil) to Jun. 2023 (HK$2,006.78 Mil) and
increased
from Jun. 2023 (HK$2,006.78 Mil) to Dec. 2023 (HK$2,157.25 Mil).
Zhaoke Ophthalmology's annual market cap
declined
from Dec. 2021 (HK$3,089.10 Mil) to Dec. 2022 (HK$1,642.41 Mil) but then
increased
from Dec. 2022 (HK$1,642.41 Mil) to Dec. 2023 (HK$2,157.25 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Zhaoke Ophthalmology's Enterprise Value for Today is HK$-523.36 Mil.
Zhaoke Ophthalmology Market Cap Historical Data
The historical data trend for Zhaoke Ophthalmology's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Zhaoke Ophthalmology's Market Cap
For the Biotechnology subindustry, Zhaoke Ophthalmology's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhaoke Ophthalmology's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhaoke Ophthalmology's Market Cap distribution charts can be found below:
* The bar in red indicates where Zhaoke Ophthalmology's Market Cap falls into.
Zhaoke Ophthalmology Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Zhaoke Ophthalmology's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhaoke Ophthalmology (HKSE:06622) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Zhaoke Ophthalmology Market Cap Related Terms
Thank you for viewing the detailed overview of Zhaoke Ophthalmology's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Zhaoke Ophthalmology (HKSE:06622) Business Description
Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company. It is dedicated to the research, development, and commercialization of therapies that address unmet medical needs in China. The company has built a comprehensive ophthalmic drug pipeline of 26 candidates that covers ocular indications affecting the front and the back of the eye, through either in-house development or in-licensing. It has also established an ophthalmic manufacturing facility and is assembling an experienced marketing team in anticipation of a near-term product launch.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:06622 has been successfully added to your 